Sukohar, Asep and HERAWATI, HENING and Siberio, Hendra T and Gigih, Setiawan and Graharti, Risti and Wahyudo, Riyan and Morfi, Chicy Widya (2018) Effects of Caffeine Againts Expression on Mir-423-3p in Cell Lines Hep-G2. Biomedical & Pharmacology Journal, 11 (1). pp. 429-435. ISSN 0974-6242

[img] Text

Download (185kB)
Official URL:


The development of anticancer drugs from nature’s ingredientsare very attracted for world researchers. Caffeine contained in coffee has long been scrutinized as anticancer hepar, researched in invitro on cancer cell hepatocelluler (HCC) and rats. Hepatocelluler cancer (HCC) is one of five vicious cancers in the world, requiring better management and early detection. Micro RNA (mir) is a nucleotide composing 19-20 pairs of bases that can be used as diagnostic, therapeutic and preventive or early detection of cancer. We have examined the expression of miRNA 146 A, mir-103, 423-3 p, 16, 21, and in this study, we focus on the mir-423-3p which are treated caffeine 0.5 mM. The purpose of this research was to assess the influence of caffeine 0.5 mM against Hep-G2 cells by assessing expression of mir-423-3p. The study was carried out using invitro cell Hep-G2, with 30 groups of sample consisting of 15 sample controls and 15 samples treated 0.5 mM caffeine, using qPCR CFX-96 type and expression of mir-423-3p analyzed by the Livaks method. Expression of mir-423-3p examined at 0, 2, 8, 18 and 24. There is a variation in the expression of mir-423-3p from 0 hours to 24 hours after treating caffeine 0.5 mM. Expression of mir-423-3p lowest is in the Group 8 and 18 hours after treating caffeine 0.5 mM (0.11), the highest expression at 0 hours(0.26) and the value of the expression on the 24th hour (0.17). Caffeine decreased expression of mir-423-3p. Keywords:Caffeine, Expression of mir-423-3p, Hep-G2.

Item Type: Article
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Fakultas Kedokteran (FK) > Prodi Pendidikan Dokter
Depositing User: Dr. ASEP SUKOHAR
Date Deposited: 26 Jun 2018 02:44
Last Modified: 26 Jun 2018 02:44

Actions (login required)

View Item View Item